DOCSLIB.ORG

Proxy Statement 2015 Annual Report Meet Eve

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proxy Statement 2015 Annual Report Meet Eve JAZZ PHARMACEUTICALS PLC PROXY STATEMENT 2015 ANNUAL REPORT MEET EVE Our cover highlights Eve. Soon after becoming a nurse, Eve was diagnosed with leukemia and began receiving intensive cycles of chemotherapy to combat her disease. As part of her leukemia treatment, her physician recommended a hematopoietic stem cell transplant (HSCT). Shortly after her transplant, Eve became very ill and was diagnosed with hepatic veno-occlusive disease (VOD), a rare, life-threatening complication of HSCT. Through an expanded access treatment-investigational new drug protocol in the U.S., Eve received defibrotide, an investigational drug at the time, to manage this complication. To celebrate her recovery, Eve and her husband expanded their family with a new puppy. Today, Eve has resumed nursing to provide patients with the same great care she received during the management of her leukemia and HSCT. On March 30, 2016, the U.S. Food and Drug Administration granted marketing approval for Defitelio® (defibrotide sodium) for the treatment of adult and pediatric patients with hepatic VOD, also known as sinusoidal obstruction syndrome, with renal or pulmonary dysfunction following HSCT. Making a real difference in patients’ lives is at the center of everything we do. The patient story shared in this communication depicts an individual patient’s response to our medicine and is not representative of all patient responses. June 20, 2016 Dear Shareholders, 2015 was another successful year for Jazz Pharmaceuticals. We delivered solid top- and bottom-line growth, while continuing to focus on improving patients’ lives by identifying, developing and delivering clinically meaningful products to patients with disabling or potentially fatal diseases. We executed on our corporate strategy and business model through organic growth of our key marketed products, expansion of lifecycle management programs for our commercial products, and advancement of our clinical development pipeline, including a focus on the evaluation of new indications for our product candidate, JZP-110. We remained active in our corporate development initiatives by evaluating a broad set of acquisition and licensing opportunities. We use a defined set of criteria to identify well-differentiated, clinically meaningful, long-lived products or product candidates that we believe will generate appropriate returns to shareholders. While we did not complete a transaction in 2015, this disciplined approach allowed us to further strengthen our cash position and expand our borrowing capacity, and has positioned us well for future corporate development activities. We achieved a key milestone in 2015 by completing the submission of our new drug application for defibrotide to the U.S. Food and Drug Administration (FDA). On March 30, 2016, the FDA approved Defitelio® (defibrotide sodium) for the treatment of adult and pediatric patients with hepatic VOD with renal or pulmonary dysfunction following HSCT. Defitelio became commercially available in the U.S. in April 2016. Financial performance highlights in 2015 • Total revenues of $1.3 billion, an increase of 13% over 2014, driven primarily by sales of our lead marketed product, Xyrem® (sodium oxybate) oral solution. • GAAP net income attributable to Jazz Pharmaceuticals plc of $329.5 million and adjusted net income attributable to Jazz Pharmaceuticals plc of $600.1 million, an increase of 15% over 2014. • GAAP net income per diluted share attributable to Jazz Pharmaceuticals plc of $5.23 and adjusted net income per diluted share attributable to Jazz Pharmaceuticals plc of $9.52, an increase of 15% over 2014. Other 2015 milestones • In February 2015, the FDA approved the final Xyrem risk evaluation and mitigation strategy (REMS), which we implemented in August 2015. • We initiated patient enrollment in our Phase 3 clinical program for JZP-110 for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy and for the treatment of EDS in patients with obstructive sleep apnea in the second quarter. • We continued to repurchase our ordinary shares under share repurchase programs authorized by our board of directors. In 2015, we spent a total of $62 million to repurchase 0.4 million of our ordinary shares under the repurchase programs. • We completed construction of a 54,000 square foot manufacturing and development facility in Ireland in late 2015. Continued execution of our corporate growth strategy In 2016, we look forward to delivering on key financial, commercial and R&D goals that have the potential to drive significant value creation. Our R&D goals for 2016 include obtaining preliminary data from our three Phase 3 safety and efficacy studies of JZP-110 and initiating our Phase 3 study evaluating defibrotide for the prevention of VOD following HSCT in high risk patients, in pursuit of our goal of generating important new therapeutic options for patients. With our strong balance sheet and overall market valuations that are more conducive to transactions that could generate strong returns, we are focused and prepared to execute on corporate development opportunities that have the potential to expand the business and deliver long-term value for our shareholders. We thank you for your ongoing support as we focus on our mission of delivering meaningful products to patients. Sincerely, Bruce C. Cozadd Chairman and Chief Executive Officer Total Revenues 2015 Worldwide Net Product Sales (in millions) $1,400 $1,325 $1,200 $1,173 ERWINAZE/ DEFITELIO/ $1,000 ERWINASE DEFIBROTIDE $872 PRIALT/ $800 OTHER XYREM $600 $400 $200 $0 2013 2014 2015 Net Income Attributable to Jazz Pharmaceuticals plc Net Income Attributable to Jazz Pharmaceuticals plc (in millions) Per Diluted Share GAAP GAAP Non-GAAP Adjusted (unaudited) 1 Non-GAAP Adjusted (unaudited) 1 $700 $10.00 $9.52 $600 $600 $8.31 $520 $8.00 $500 $6.26 $400 $385 $6.00 $5.23 $330 $300 $3.51 $216 $4.00 $200 $2.00 $100 $582 $0.932 $0 $0 2013 2014 2015 2013 2014 2015 1. Represents adjusted net income attributable to Jazz Pharmaceuticals plc (and the related per share amounts), which are non-GAAP financial measures that exclude certain items from GAAP reported net income attributable to Jazz Pharmaceuticals plc (and the related per share amounts). Reconciliations of GAAP reported net income attributable to Jazz Pharmaceuticals plc (and related per share amounts) to non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc (and related per share amounts) for each period presented can be found under the heading “Non-GAAP Financial Measures” in Part II, Item 7 of the enclosed Annual Report on Form 10-K for the year ended December 31, 2015. 2. For 2014, GAAP reported net income attributable to Jazz Pharmaceuticals plc included acquired in-process research and development costs of $203 million, or approximately $3.24 per diluted share, primarily relating to rights for JZP-110 and rights for defibrotide in the Americas. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY Registered in Ireland – No. 399192 Fourth Floor, Connaught House One Burlington Road Dublin 4, Ireland NOTICE OF 2016 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 4, 2016 Proxy Dear Shareholder: You are cordially invited to attend the 2016 annual general meeting of shareholders (the “annual meeting”) of Jazz Pharmaceuticals plc, a public limited company formed under the laws of Ireland (the “company”). The annual meeting will be held on Thursday, August 4, 2016, at 10:00 a.m. local time at our corporate headquarters located at Fourth Floor, Connaught House, One Burlington Road, Dublin 4, Ireland, for the following purposes: 1. To elect by separate resolutions the four nominees for director named in the accompanying proxy statement (the “proxy statement”) to hold office until the 2019 annual general meeting of shareholders (Proposal 1). 2. To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as the independent auditors of the company for the fiscal year ending December 31, 2016 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine the independent auditors’ remuneration (Proposal 2). 3. To approve, on a non-binding advisory basis, the compensation of the company’s named executive officers as disclosed in the accompanying proxy statement (Proposal 3). 4A. To approve amendments to the company’s memorandum of association to make certain administrative adjustments to address the enactment of the Irish Companies Act 2014 and a minor housekeeping matter (Proposal 4A). 4B. To approve amendments to the company’s articles of association to make certain administrative adjustments to address the enactment of the Irish Companies Act 2014 and certain minor housekeeping matters (Proposal 4B). 5. To authorize the company and/or any subsidiary of the company to make open market purchases of the company’s ordinary shares (Proposal 5). 6. To renew the board of directors’ existing authority under Irish law to allot and issue ordinary shares (Proposal 6). 7. To renew the board of directors’ existing authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply (Proposal 7). 8. To approve any motion to adjourn the annual meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve any or all of Proposals
Load more

Recommended publications
  • Final Attendee List
    Jennifer Abnet GlaxoSmithKline I GlaxoSmithKline I Jane Arboleda APRN Guardant I Molly Benson Sanjiv Agarwala MD Puma Biotechnology I Cancer Expert Now I Joe Arminger AbbVie I Seth Berkowitz LCSW, Manmeet Ahluwalia MD, CCLS MBA Patricia Armstrong The Leukemia & Lymphoma Miami Cancer Institute I Novartis I Society V Steve Albers Kim Arnold APRN CPNP Barry Berman MD, MS Alexion V CPHON Florida Cancer Specialists I Servier Pharmaceuticals I Maritza Alencar DNP, Tizano Bernard MBA, APRN, BMTCN Sheila Arrington MSN, Cancer Care Centers of Miami Cancer Institute V APRN, NP-C, AOCN Brevard I Puma Biotechnology I Carmen Allen MSIT Ana Mari Bernardini Pharmavoxx V Shannon Ashmon Novartis Oncology I Eisai, Inc I Luly Almeida Bernard Berry MBA Incyte Corporation I Sarah Ashton MS AstraZeneca Pharmaceuticals Guardant Health I I Talat Almukhtar MD Orlando Health Cancer Melissa Austin Jason Bever Institute I Cancer Care Centers of Oncopeptides I Brevard I Beatrice Alvarado Roberts Amy Bignon MD Garland Avera Doyle Caris Life Sciences I University of Florida I Jazz Pharmaceuticals I Nadeem Bilani MD Tadeu Ambros MD Francie Babcock Cleveland Clinic I FCS I AMAG Pharmaceuticals/Covis I Angela Bilik RN BSN Douglas Anderson AstraZeneca I Incyte Corporation I Craig Bailey Astra Zeneca I Jamie Bilsky BS Blesson Andrews Genentech V Genentech I Kevin Barr Daiichi Sankyo I Rohit Bishnoi MD Ollie Annum PharmD University of Florida I BHMCR I Leonard Bennett PharmD EMD Serono I Brady Blackman Susmitha Apuri MD MorphoSys I Florida Cancer Specialists I Michael Bennett As of 4-22-21 Kimberly Blandon RN MSN Rick Breitenstein Memorial Cancer Institute I Apellis Pharmaceuticals I Denise Capo Karyopharm Therapeutics I Taryn Boiteau GlaxoSmithKline I Amanda Bridges Florida Society of Clinical Heidi Caravetta Tracy Bonds RN, BSN, Oncology I Exelixis, Inc.
    [Show full text]
  • Q1 Pharma Sector Snapshot
    SPECIALTY & GENERIC PHARMA Q1 2021 Report Market Commentary – Debt Capital Markets Debt Markets ▪ 2020 saw increased amounts of debt used in buyouts across the board, resulting in the highest debt / EBITDA Median US Buyout Multiples levels since 2014 − The increased use of debt was driven by 2H20 back- end loaded lending activity (primarily 4Q20) as 16.0x 12.7x 14.1x 12.2x 12.0x 11.6x 11.5x certainty around the U.S. election and vaccination 11.1x 10.0x 9.8x 12.0x 9.7x expectations increased 9.4x 8.6x 8.3x 8.2x 7.5x 7.8x 5.2x 6.7x 5.7x 5.6x ▪ 8.0x 5.9x As the effects of COVID now begin to diminish, debt 5.4x 4.4x 4.1x 3.7x 4.6x 4.3x 3.8x markets have seemingly recovered, signaling that 3.6x lenders have become increasingly comfortable with 4.0x 4.3x 6.9x 6.5x 6.3x 6.0x 5.9x 5.7x 5.7x 5.7x 5.7x 5.6x 5.3x 4.5x 4.4x macroeconomic and company-specific fundamentals 4.3x 0.0x 3.2x − With increased confidence, lenders are currently looking to provide strong leverage for high-quality assets, particularly ones that have proven their Debt/EBITDA Equity/EBITDA EV/EBITDA stability through the recent market downturn Source: PitchBook ▪ The spread on U.S. high-yield debt has returned to pre- Historical US High Yield Debt Effective Yield COVID levels − 4.22% current effective yield compared with a 12.0% 11.4% 11.38% effective yield on March 23, 2020 (peak of the pandemic) 9.0% ▪ We expect increased activity by lenders in 2021 due to: 6.0% 4.2% − Pent-up demand in M&A activity driven by the impact of COVID 3.0% − Limited Partner agreements and investor
    [Show full text]
  • Perrigo Needs Deal to Thwart Mylan
    November 02, 2015 Perrigo needs deal to thwart Mylan Madeleine Armstrong Perrigo continues to resist Mylan’s overtures, but a deal is looking increasingly likely after its attempts to block the buy in court failed. Mylan has until November 13 to tempt Perrigo shareholders under Irish takeover rules. An acquisition of its own might now be the only hope for Perrigo in this buy-or-be-bought saga. But, with increasing consolidation in the speciality pharma space, the pool of potential targets is dwindling (see table below). The best option looks like Endo International, though its market cap of nearly $14bn might make it too big a bite for Perrigo, which has just $5bn in cash. But if Perrigo could pull it off it would gain a company with one of the best forecast growth rates in mid-tier pharma. Jazz Pharmaceuticals, Meda or Lundbeck could be easier to digest but the last, with faltering sales, might not be such an attractive proposition. Perrigo and its potential acquisition targets Company Based Market cap ($bn) 2014 sales ($m) 2020e sales ($m) CAGR Perrigo Ireland 23.1 815 1,388 +9% Endo International US 13.6 2,053 5,616 +18% Jazz Pharmaceuticals Ireland 8.4 1,163 2,151 +11 Lundbeck Denmark 5.9 2,222 1,974 -2% Meda Sweden 5.4 1,963 2,519 +4% Last line of defence Perrigo’s chief executive, Joseph Papa, is standing firm but the company’s share price closed down 5% at $157.74 on Friday, well off its 2015 high of $203.69 in April after Mylan formalised its bid (Mylan anti-chain action as good as confirms Teva interest, April 09, 2015).
    [Show full text]
  • Generic Pharma
    SPECIALTY/GENERIC PHARMA SECTOR SNAPSHOT April 2019 Branded Specialty Pharma – Transaction Comps USD in millions Announced Geographic Enterprise EV / EV / Date Target Target Description Buyer Location Value LTM Revenue LTM EBITDA LTM Revenue LTM EBITDA Specialty pharmaceutical company focused in hospital InvaGen Nov-18 Avenue Therapeutics USA $210.2 NA NA NA NA products Pharmaceuticals Specialty pharmaceutical company focused in Oct-18 Corium International Gurnet Point Capital USA $492.5 $36.5 ($44.0) 13.5x NM transdermal and transmucosal products NextWave Specialty pharmaceutical company focused in Sep-18 Tris Pharma USA NA NA NA NA NA Pharmaceuticals pediatric CNS products Specialty pharmaceutical company focused in opioid Aug-18 Adapt Pharma Emergent BioSolutions Ireland $719.8 NA NA NA NA abuse products Sylvant from Johnson & Branded product for the treatment of Casteleman's Jul-18 EUSA Pharma Ireland $115.0 NA NA NA NA Johnson disease Femring in US from May-18 Branded women's health products Millicent Pharma USA $75.0 $23.0 $17.0 3.3x 4.4x Allergan Pancreaze from Johnson & Branded pancreatice enzyme replacement therapy May-18 VIVUS USA $135.0 $35.2 -- 3.8x -- Johnson product Specialty pharmaceutical company with focus across May-18 Willow Biopharma VIVUS Canada NA NA NA NA NA various therapeutic areas Large pharmaceuctical company with products across Apr-18 Shire Takeda Pharmaceutical Ireland $80,535.0 $15,354.0 $6,449.9 5.2x 12.5x a range of therapeutic areas and geographies Specialty pharmaceutical company focused on Feb-18 Altius
    [Show full text]
  • Management Team
    Management Team Bruce C. Cozadd Executive Chairman Bruce Cozadd joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Mr. Cozadd served as a consultant to companies in the biopharmaceutical industry. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company now owned by Johnson & Johnson, most recently as its Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. Mr. Cozadd serves on the boards of Cerus Corporation, a biopharmaceutical company; Threshold Pharmaceuticals, a biotechnology company; and The Nueva School and Stanford Hospital and Clinics, both non-profit organizations. Samuel R. Saks, MD Chief Executive Officer Samuel Saks, M.D., joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Dr. Saks was Company Group Chairman of ALZA Corporation and served as a member of the Johnson & Johnson Pharmaceutical Group Operating Committee. From 1992 until 2001, he held various positions with ALZA Corporation, most recently as its Chief Medical Officer and Group Vice President, where he was responsible for clinical and commercial activities. Dr. Saks received a B.S. and an M.D. from the University of Illinois. Dr. Saks serves on the board of Trubion Pharmaceuticals and Cougar Biotechnology. Robert M. Myers President Robert Myers joined Jazz Pharmaceuticals at its inception and was appointed as Jazz Pharmaceuticals’ President in March 2007.
    [Show full text]
  • Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 08/08/2015 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 21:25:58 REPORT ID 2794D052 PAGE: 01 ALPHA COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 10/01/2015 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 68782 (OSI) EYETECH 65162 AMNEAL PHARMACEUTICALS LLC 00074 ABBOTT LABORATORIES 69238 AMNEAL PHARMACEUTICALS, LLC 68817 ABRAXIS BIOSCIENCE, LLC 53150 AMNEAL-AGILA, LLC 16729 ACCORD HEALTHCARE INCORPORATED 00548 AMPHASTAR PHARMACEUTICALS, INC. 42192 ACELLA PHARMACEUTICALS, LLC 66780 AMYLIN PHARMACEUTICALS, INC. 10144 ACORDA THERAPEUTICS, INC. 55724 ANACOR PHARMACEUTICALS 00472 ACTAVIS 10370 ANCHEN PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 62559 ANIP ACQUISITION COMPANY 45963 ACTAVIS INC. 54436 ANTARES PHARMA, INC. 46987 ACTAVIS KADIAN LLC 52609 APO-PHARMA USA, INC. 49687 ACTAVIS KADIAN LLC 60505 APOTEX CORP. 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED 63323 APP PHARMACEUTICALS, LLC. 67767 ACTAVIS SOUTH ATLANTIC 42865 APTALIS PHARMA US, INC 66215 ACTELION PHARMACEUTICALS U.S., INC. 58914 APTALIS PHARMA US, INC. 52244 ACTIENT PHARMACEUTICALS 13310 AR SCIENTIFIC, INC. 75989 ACTON PHARMACEUTICALS 08221 ARBOR PHARM IRELAND LIMITED 76431 AEGERION PHARMACEUTICALS, INC. 60631 ARBOR PHARMACEUTICALS IRELAND LIMITED 50102 AFAXYS, INC. 24338 ARBOR PHARMACEUTICALS, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 59923 AREVA PHARMACEUTICALS 27241 AJANTA PHARMA LIMITED 76189 ARIAD PHARMACEUTICALS, INC. 17478 AKORN INC 24486 ARISTOS PHARMACEUTICALS, INC. 24090 AKRIMAX PHARMACEUTICALS LLC 67877 ASCEND LABORATORIES, L.L.C. 68220 ALAVEN PHARMACEUTICAL, LLC 76388 ASPEN GLOBAL INC. 00065 ALCON LABORATORIES, INC. 51248 ASTELLAS 00998 ALCON LABORATORIES, INC. 00469 ASTELLAS PHARMA US, INC. 25682 ALEXION PHARMACEUTICALS 00186 ASTRAZENECA LP 68611 ALIMERA SCIENCES, INC.
    [Show full text]
  • Manufacturers with Signed Rebate Agreements February 1 , 2011
    Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements February 1 , 2011 NEWLABELER NAME START END SC NEW LABELER NAME START END SC 00002 ELI LILLY AND COMPANY 1/1/1991 Y 00126 COLGATE ORAL PHARMACEUTICAL 1/1/1991 Y 00003 E R SQUIBB AND SONS INC. 1/1/1991 Y 00131 SCHWARZ PHARMA, INC. 1/1/1991 Y 00004 HOFFMANN LAROCHE INC 1/1/1991 00132 C B FLEET COMPANY INC. 1/1/1991 00005 LEDERLE LABORATORIES 1/1/1991 Y 00135 SMITHKLINE BEECHAM 1/1/1995 Y 00006 MERCK SHARP & DOHME 1/1/1991 Y 00143 WEST-WARD PHARMACEUTICAL C 1/1/1991 Y 00007 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00145 STIEFEL LABORATORIES INC. 1/1/1991 Y 00008 WYETH AYERST LABORATORIES 1/1/1991 Y 00149 PROCTER & GAMBLE PHARMACEU 1/1/1991 Y 00009 PHARMACIA AND UPJOHN 1/1/1991 Y 00168 E FOUGERA AND CO, DIV OF ALTAN 1/1/1991 Y 00013 PHARMACIA AND UPJOHN 1/1/1991 Y 00169 NOVO NORDISK PHARMACEUTICAL 1/1/1991 Y 00015 INVAMED, INC 1/1/1991 Y 00172 ZENITH LABORATORIES, INC 1/1/1991 Y 00023 ALLERGAN INC. 1/1/1991 Y 00173 GLAXOSMITHKLINE 1/1/1991 Y 00024 SANOFI SYNTHELABO 1/1/1991 Y 00178 MISSION PHARMACAL COMPANY 1/1/1991 Y 00025 PHARMACIA CORPORATION 1/1/1991 Y 00182 GOLDLINE LABORATORIES INC 1/1/1991 Y 00026 BAYER CORP PHARMACEUTICAL DI 1/1/1991 Y 00185 EON LABS MANUFACTURING, INC. 1/1/1991 Y 00028 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00186 ASTRAZENECA LP 1/1/1991 Y 00029 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00187 ICN PHARMACEUTICALS INC.
    [Show full text]
  • Current Sustaining Member Companies
    CURRENT SUSTAINING MEMBER COMPANIES MEMBER FOR OVER: 10 Years 25 Years 50 Years Member Since (alphabetical order) 1976 3M Medical Solutions Division 2020 D2 Pharma Consulting, LLC 1989 J & J Health Care Systems, Inc. 2011 Remund Group, LLC 1985 Abbott Laboratories, Inc. 2007 Daiichi Sankyo, Inc. 2014 Jazz Pharmaceuticals Inc. 2018 Rigel Pharmaceuticals 2013 AbbVie Inc. 2020 Deciphera Pharmaceuticals, LLC 2007 Karl Storz Endoscopy America 2000 Sanofi 2021 Adaptive Biotechnologies 2009 Deloitte 2021 Lantheus Holdings 2020 Seattle Genetics 2017 ACADIA Pharmaceuticals, Inc. 2020 Dexcom, Inc. 2020 Lipogems 2004 Siemens Medical Solutions 2020 AcelRx Pharmaceuticals, Inc. 2020 Drip Drop Hydration 2010 LLC Federal Solutions 2019 SK Life Science, Inc. 2020 Acorda Therapeutics 2017 Eagle Pharmaceuticals, Inc. 2014 Lovell Government Services LLC 2002 Smith & Nephew, Inc. 2019 Aimmune 2005 Eisai, Inc. 2021 Mainstay Medical 2019 Sobi Inc. 2003 Alcon Laboratories, Inc. 2019 electroCore, Inc. 2014 Mallinckrodt Pharmaceuticals 2013 Stryker Orthopaedics 2019 Alexion Pharmaceuticals, Inc. 2010 Endo Pharmaceuticals 2020 MannKind Corporation 2018 Sun Pharmaceutical 2017 Alkermes, Inc. 2017 Exelixis 1999 Marketing Assessment, Inc. 1999 Sunovion Pharmaceuticals, Inc. 2019 Alnylam Pharmaceuticals 2016 Express Scripts Federal Pharmacy 2009 Masimo Corporation 2016 Taiho Oncology, Inc. 2019 Altarum Institute 2010 Federal Practitioner 2019 Medical Strategies International, LLC 2015 Takeda Oncology 2020 Amarin Corporation 2021 Ferring Pharmaceuticals Inc. 2016 Melling Medical 2000 Takeda Pharmaceutical USA, Inc. 1994 AmerisourceBergen 2018 Foundation Medicine, Inc. 1954 Merck & Co., Inc. 2020 Telemynd 1992 Amgen 2021 Frontier Technology Inc. (FTI) 2002 MerzNorth America 2020 TerSera Therapeutics 2020 Amneal Pharmaceutical 2020 Fresenius Medical Care North America 2018 Mitsubishi Tanabe Pharma America 1990 Teva 2019 Aptive Resources LLC 1989 Genentech Inc.
    [Show full text]
  • Downloads That May Be Necessary
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 20, 2018 Date of Report (Date of earliest event reported) JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-33500 98-1032470 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File No.) Identification No.) Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland (Address of principal executive offices, including zip code) 011-353-1-634-7800 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
    [Show full text]
  • Reporter's Handbook
    2O14 RE POR TER’ S HANDBOOK for the biopharmaceutical research industry Member Companies 1 Research Associates 2 U.S. Health-Related Trade and Professional Organizations 3 Government Medical and Health Contacts 4 Voluntary Health Agencies 5 International Pharmaceutical Associations/Health Care Groups 6 Key Facts/About PhRMA 7 Company Products by Category 8 Member Companies 1 Member Companies Abbott Dept 383, AP6D 100 Abbott Park Road Abbott Park, IL 60064-3500 Phone: (847) 937-6100 Fax: (847) 937-1511 Website: www.abbott.com Melissa Brotz, Corporate Public Affairs Office: (847) 935-3456 E-Mail: [email protected] Kelly Morrison, Corporate Public Affairs, Science/Policy Office: (847) 937-3802 E-Mail: [email protected] Scott Stoffel, Corporate Public Affairs, Financial Office: (847) 936-9502 E-Mail: [email protected] Steve Chesterman, Medical Optics Office: (714) 247-8711 E-Mail: [email protected] Jonathon Hamilton, Vascular Devices 3200 Lakeside Drive, Suite 355 Santa Clara, CA 95054 Office: (408) 845-3491 E-Mail: [email protected] AbbVie 1 North Waukegan Road North Chicago, IL 60064 Phone: (847) 932-7900 Website: www.abbvie.com Gulden Mesara, Vice President, Global Commercial and Health Communications Office: (847) 938-2804 E-Mail: [email protected] Angela Sekston, Vice President, Leadership and Employee Communications Office: (847) 937-6636 E-Mail: [email protected] Morry Smulevitz, Head of U.S. Public Affairs Office: (847) 937-2152 E-Mail: [email protected] 1-1
    [Show full text]
  • Representative Healthcare and Life Sciences M&A Transactions
    Representative Healthcare and Life Sciences M&A Transactions • Medtronic plc. Representing Medtronic plc in its $458 million acquisition of Twelve, Inc., a developer of devices for the treatment of chronic cardiovascular diseases. • Shire plc. Representing Shire plc in its $30 billion acquisition of Baxalta Incorporated, a developer of products for the treatment of hematology and immunology worldwide. • Pfizer Inc. Representing Pfizer Inc. in its $130 million acquisition of GlaxoSmithKline plc, a UK-based pharmaceuticals company. • Pfizer Inc. Representing Pfizer Inc. in its $17 billion acquisition of Hospira Inc., a provider of injectable drugs and infusion technologies. • Wright Medical Group. Representing Wright Medical Group in its $3.3 billion merger of equals with Tornier N.V., a Netherlands-based medical device company. • Synageva BioPharma. Represented Synageva BioPharma in its $8 billion sale to Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. • Pfizer Inc. Represented Pfizer Inc. in its investment in AM-Pharma B.V., an Amsterdam-based biopharmaceutical company. • Becton, Dickinson & Company. Represented Becton, Dickinson & Company in its acquisition of CRISI Medical Systems, Inc., a medical device company, focuses on the development of drug-delivery systems. • Cubist Pharmaceuticals. Represented Cubist Pharmaceuticals in its $9 billion sale to Merck & Co. Inc., a provider of health care solutions worldwide. • Symmetry Medical. Represented Symmetry Medical Inc. In the sale of OEM Solutions business to Tecomet, a Genstar Capital portfolio company, for $450 million. As part of the deal, Symmetry, a publicly held medical device solutions provider, will also spin off and transfer to its shareholders ownership in a new company, Specialty Surgical Instruments.
    [Show full text]
  • Major Employers of Chemists in the Northeastern Section
    Major Employers of Chemists in the Northeastern Section by Don Rickter with valuable assistance from Karen Piper, Mike Filosa, Lee Johnson, Dorothy Phillips and others Eastern Massachusetts and New Hampshire are a hotbed of dynamic chemistry companies. Some are start-ups that will grow dramatically. There are dozens of companies in both states. Some will merge or be acquired or change their names. Each has a unique personality and spectrum of expertise. The following list is most of the employers of seven or more members of the American Chemical Society — as of the end of May 2010. A few of the larger employers, with more than 35 ACS chemists, are in ALL CAPS. The locations are in eastern Massachusetts — unless marked with NH for New Hampshire. Aerodyne Research BIOGEN IDEC Cubist Pharmaceuticals Billerica CAMBRIDGE Lexington www.aerodyne.com/ www.biogenidec.com/ www.cubist.com Alkermes Inc. Boston Scientific Corp. Dow Electronic Materials Waltham Natick Marlborough www.alkermes.com/ www.bostonscientific.com/ www.dow.com/ & home.bsci www.rohmhaas.com/ Alnylam Pharmaceuticals Broad Institute [rhymes DSM-Neoresins Cambridge with road] Cambridge Wilmington www.alnylam.com/ www.broadinstitute.org/ www.dsm.com/en_US/htm l/dnr/home. htm AMGEN INC. Bruker Corp. CAMBRIDGE Billerica www.bruker.com E-Ink Corp. www.amgen.com/ Cambridge www.e- Cabot Corp. ink.com Ariad Pharmaceuticals Billerica www.cabot- Cambridge corp.com EISAI RESEARCH www.ariad.com/ INSTITUTE Cambridge Isotope Labs ANDOVER Arqule Inc. Andover www.easai.com Woburn www.arqule.com/ www.isotope.com/ EMD Serono ASTRA ZENECA Concert Pharmaceuticals Rockland WALTHAM Lexington www.emdserono.com www.astrazeneca.com/ www.concertpharma.com Enanta Pharmaceuticals Microbia (Also see Physical Sciences Inc.
    [Show full text]